Michael Makris/LinkedIn
Oct 30, 2025, 03:53
Michael Makris on Biomarin’s Decision to Divest Roctavian
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Biomarin, the only manufacturer of an approved hemophilia A gene therapy has decided to divest Roctavian and remove it from their portfolio.
They plan to sell it on to a more established hemophilia company, if they can find a buyer.
The problems have been the high cost and limited durability.
This is a sad turn of events but not surprising to anybody who follows the field.
We suspected that sales were poor, but not this poor, as indicated in their press release.
This is their press release.”
Stay updated with Hemostasis Today.
-
Jun 4, 2026, 15:10Dipanjana Datta: Genetic Spectrum of Hemophilia and Carrier Screening in Families of Persons with Hemophilia
-
Jun 4, 2026, 15:07Zain Khalpey: Key Differences Between NSTEMI and STEMI
-
Jun 4, 2026, 15:06Faisal Alghamdi: Iron Overload in Thalassemia Is Preventable – But Prevention Takes More Than Prescribing Drugs
-
Jun 4, 2026, 14:52Seema Dawood: Hemoglobin Typing Interpretation
-
Jun 4, 2026, 13:58Dietmar Dammerer: How Should We Manage Traumatic Brain Injury When on Anticoagulants?
-
Jun 4, 2026, 13:54Yaariv Khaykin: AI ECG Analysis Uncovers Hidden AF Associated With Future Stroke Risk
-
Jun 4, 2026, 13:50Gene Nudelman: Can a Hemostatic Gauze Perform When Blood Clotting is Impaired?
-
Jun 4, 2026, 13:45Edward Lee Carter: The First-Ever AHA/ACC Acute PE Guideline Is Here
-
Jun 4, 2026, 13:38Denis Oduor: The Role of Expectant Fathers in Saving Mothers and Newborns